NEW YORK (GenomeWeb News) – Lab21 has licensed worldwide rights to a suite of patents from Cooperative Diagnostics covering real-time PCR technology that the firm will incorporate into molecular diagnostic kits.
The Cambridge, UK-based diagnostic products and services firm said that as part of the agreement it has exclusive use of the technology on a set of biomarker targets for the oncology and infectious disease areas. Financial and other terms of the pact were not disclosed.
"The Cooperative Diagnostics technologies bring powerful new tools to our development capability including fifth-generation real-time PCR technology and we expect to launch our first CE marked companion diagnostic assays using this technology during the first half of 2012," Lab21 CEO Graham Mullis said in a statement. "These tests will be commercialized through our international distribution networks and particularly through our key global OEM partners."